IFRX_OUT_1 [2025-04-29 10:44:20 -0400] 5854 Bytes | 1673 tokens | Cum: 1673 tkns (20.91% of 8k)
==========================================================================

By the grace of fortune and the swing of fate, InflaRx N.V. Common (IFRX) hath moved from $1.22 to $1.39. 'Tis 10:44 AM on Tue Apr 29, 2025. We must needs inquire—doth this path lead unto riches or ruin?

--- COMPANY PROFILE ---
Company: InflaRx N.V. Common (IFRX)
IPO: 2017-11-08 (7 Years Ago)
Market Cap: $66,012,146
Shares Outstanding: 67,130,000
Exchange: XNAS
Description: InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Here’s a list of headlines for InflaRx N.V. Common:

Apr-02-25 03:33PM - Is InflaRx (IFRX) the Best German Stock to Buy According to Hedge Funds?
Mar-26-25 09:35AM - InflaRx (IFRX) Loses -15.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Mar-20-25 07:30AM - InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones
Mar-19-25 06:00PM - Here's the major earnings before the open tomorrow
Mar-07-25 08:00AM - InflaRx Showcases Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting
Feb-28-25 09:00AM - InflaRx to Showcase Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting
Feb-25-25 07:30AM - InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences
Feb-18-25 04:01PM - InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
Feb-13-25 09:45PM - InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
Feb-13-25 09:45PM 04:01PM - InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants
Jan-23-25 07:30AM - InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference
Jan-16-25 11:05AM - InflaRx wins EU approval for Gohibic in Covid-19-induced ARDS
Jan-15-25 12:30PM - InflaRx Receives European Commission Approval for GOHIBIC (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)
Jan-07-25 07:30AM - InflaRx Announces Participation in January Events in San Francisco
Dec-20-24 07:30AM - InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904
Nov-19-24 06:29PM - Is InflaRx N.V. (IFRX) the Best German Stock to Buy Now?
Nov-15-24 07:51AM - InflaRx Receives Positive CHMP Opinion for GOHIBIC (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome
Nov-12-24 11:00PM - InflaRx Reports Q3 2024 Financial Results and Progress
Nov-09-24 07:41AM - InflaRx expects cash to fund operations into 2026
Nov-08-24 08:40AM - InflaRx N.V. (IFRX) Reports Q3 Loss, Tops Revenue Estimates
Nov-08-24 08:40AM 07:30AM - InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update
Oct-31-24 07:30AM - InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-02-14T02:45:00Z - InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
B2 - 2024-11-15T12:51:00Z - InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome
B3 - 2024-06-24T12:02:00Z - InflaRx’s GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)
B4 - 2024-05-21T18:30:00Z - InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators
B5 - 2024-05-08T11:30:00Z - InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update
B6 - 2024-04-24T11:30:00Z - InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for InflaRx N.V. Common (IFRX).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

IFRX_OUT_3 [2025-04-29 10:44:20 -0400] 955 Bytes | 287 tokens | Cum: 1962 tkns (24.52% of 8k)
==========================================================================

Showing B2 (chunk 1 of 1): B2:
**InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/11/15/2981948/0/en/InflaRx-Receives-Positive-CHMP-Opinion-for-GOHIBIC-Vilobelimab-for-the-Treatment-of-SARS-CoV-2-Induced-Acute-Respiratory-Distress-Syndrome.htmlInflaRx's anti-C5a antibody vilobelimab has received a positive opinion from the CHMP of the EMA for the treatment of SARS-CoV-2-induced ARDS. The positive opinion is based on the results of the PANAMO trial, which showed improved survival with vilobelimab treatment.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

IFRX_OUT_5 [2025-04-29 10:44:21 -0400] 380 Bytes | 87 tokens | Cum: 2051 tkns (25.64% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

IFRX_OUT_7 [2025-04-29 10:44:22 -0400] 336 Bytes | 98 tokens | Cum: 2151 tkns (26.89% of 8k)
==========================================================================

Showing A1 (chunk 1 of 1): A1:
Document A1 not found. Only 0 articles available.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

IFRX_OUT_9 [2025-04-29 10:44:23 -0400] 238 Bytes | 59 tokens | Cum: 2212 tkns (27.65% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

IFRX_OUT_11 [2025-04-29 10:44:24 -0400] 251 Bytes | 78 tokens | Cum: 2293 tkns (28.66% of 8k)
==========================================================================

You just read a chunk of S1.
You may now:
- Say "MOR" to continue this article
- Say "S2", "S3", etc. to request another
- Or say "NEX" to move to the next source

You are allowed up to 6 articles from this list. If you’re ready to move on, say NEX.

IFRX_OUT_13 [2025-04-29 10:44:31 -0400] 5050 Bytes | 1236 tokens | Cum: 3532 tkns (44.15% of 8k)
==========================================================================

This is our set of metrics for InflaRx N.V. Common.
Please analyze the numbers.

+---------------------+-----------------------+-------------------------+--------------------------+
| Volume: 54,312 | Perf Month: 15.65% | Option/Short: Yes / Yes | Sales Y/Y TTM: 178.84% |
+---------------------+-----------------------+-------------------------+--------------------------+
| Avg Volume: 404.96K | Perf Quarter: -40.89% | Short Float: 1.62% | ROE: -62.38% |
+---------------------+-----------------------+-------------------------+--------------------------+
| Rel Volume: 0.71 | Index: - | Short Ratio: 2.28 | ROI: -84.03% |
+---------------------+-----------------------+-------------------------+--------------------------+
| RSI (14): 58.61 | Market Cap: 89.28M | Short Interest: 0.92M | Sales Surprise: -100.08% |
+---------------------+-----------------------+-------------------------+--------------------------+
| ATR (14): 0.13 | Shs Outstand: 58.88M | Beta: 1.64 | EPS Surprise: 59.80% |
+---------------------+-----------------------+-------------------------+--------------------------+
| SMA20: 21.91% | Shs Float: 57.08M | Sales Q/Q: 105.64% | P/E: - |
+---------------------+-----------------------+-------------------------+--------------------------+
| SMA50: 6.66% | Inst Own: 19.36% | Sales past 5Y: 32.59% | Earnings: Mar 20 BMO |
+---------------------+-----------------------+-------------------------+--------------------------+
| SMA200: -22.27% | Insider Own: 14.98% | Employees: 74 | |
+---------------------+-----------------------+-------------------------+--------------------------+
| Perf Week: 14.66% | Insider Trans: 0.00% | Debt/Eq: 0.01 | |
+---------------------+-----------------------+-------------------------+--------------------------+

The next section covers any insider trading by InflaRx N.V. Common officers or majority shareholders (if available).

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: N/A
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.39
Average Volume: 301242.0
30-Day High: 1.39
30-Day Low: 0.9
No detailed financial data available.
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of InflaRx N.V. Common (IFRX).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about InflaRx N.V. Common.

2) MARKET_SCORE[]
This conversation was initiated because IFRX is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for IFRX.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, IFRX could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect IFRX to increase 50% from its current price of $0.98, say: PRICE_TARGET[1.47]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of InflaRx N.V. Common.

11) ETHICAL_RATING[]
Rate InflaRx N.V. Common’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of InflaRx N.V. Common.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

IFRX_IN_15 [2025-04-29 10:44:32 -0400] 126 Bytes | 29 tokens | Cum: 3775 tkns (47.19% of 8k)
==========================================================================

====================================
[2025-04-29 10:44:32] # Analysis Completed
Elapsed Time: 13.53 seconds